Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 184.78B |
| Revenue (ttm) | 54.17B |
| Net Income (ttm) | 13.97B |
| Shares Out | n/a |
| EPS (ttm) | 5.52 |
| PE Ratio | 13.23 |
| Forward PE | 9.39 |
| Dividend | 2.91 (3.88%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 3,370 |
| Average Volume | 3,756 |
| Open | 75.80 |
| Previous Close | 75.50 |
| Day's Range | 75.00 - 76.20 |
| 52-Week Range | 65.50 - 102.60 |
| Beta | 0.37 |
| RSI | 60.73 |
| Earnings Date | Oct 30, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
High Margins, Lower Price: Is This Merck Stock's Buying Window?
Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Behind the Scenes of Merck & Co's Latest Options Trends
Investors with a lot of money to spend have taken a bearish stance on Merck & Co (NYSE: MRK). And retail traders should know. We noticed this today when the positions showed up on publicly available ...
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conf...
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and preve...
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 type...
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options If you purchased or acquired s...
Vaccine debate heats up as officials weigh splitting combined MMR into single doses
Medical experts and vaccine maker Merck reject HHS Deputy Secretary Jim O'Neill's suggestion to split the MMR vaccine into individual measles, mumps and rubella shots.
Merck (MRK) Declines More Than Market: Some Information for Investors
Merck (MRK) closed the most recent trading day at $87.61, moving 1.34% from the previous trading session.
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment
Arcus Biosciences shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug, a rival to Merck.
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Merck (MRK) Finalizes Acquisition of Verona Pharma
Merck (MRK) Finalizes Acquisition of Verona Pharma
Merck Completes Acquisition of Verona Pharma
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Completes Acquisition of Verona Pharma.
Merck (MRK) Finalizes $10B Acquisition of Verona Pharma
Merck (MRK) Finalizes $10B Acquisition of Verona Pharma
Merck acquisition of Verona Pharma approved by court
How to trade the health care break out
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Merck (MRK) Advances Tulisokibart with Phase 2b Trials Targeting Inflammatory Diseases
Merck (MRK) Advances Tulisokibart with Phase 2b Trials Targeting Inflammatory Diseases
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigation...
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficac...
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (Oct. 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Merck: A Race Against The Keytruda Clock
Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda.
Merck & Co's Options: A Look at What the Big Money is Thinking
Financial giants have made a conspicuous bullish move on Merck & Co. Our analysis of options history for Merck & Co (NYSE: MRK) revealed 23 unusual trades. Delving into the details, we found 47% of t...
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
MRK November 14th Options Begin Trading
Investors in Merck & Co Inc (Symbol: MRK) saw new options become available today, for the November 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRK opti...